ENTA insider transaction filings
ENANTA PHARMACEUTICALS INC — 48 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-10. Screen ENTA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-10 | 4 | Rottinghaus Scott T. — Chief Medical Officer | Tax withholding (F): 1,467 @ $13.34 | EDGAR |
| 2026-03-13 | 4 | Vance Terry — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Russell Lesley — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Peterson Kristine — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Hata Yujiro S — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | FOLETTA MARK G — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | CARTER BRUCE L A — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Kowalsky Matthew Paul — Chief Legal Officer | Grant/award (A): 1,318 @ $0 · Grant/award (A): 4,175 @ $0 · Tax withholding (F): 1,902 @ $14.25 | EDGAR |
| 2026-02-13 | 4 | Luu Brendan — Chief Business Officer | Grant/award (A): 1,575 @ $0 · Grant/award (A): 4,987 @ $0 · Tax withholding (F): 3,257 @ $14.25 | EDGAR |
| 2026-02-13 | 4 | Kieffer Tara Lynn — Chief Product Strategy Officer | Grant/award (A): 1,575 @ $0 · Grant/award (A): 4,987 @ $0 · Tax withholding (F): 3,257 @ $14.25 | EDGAR |
| 2026-02-13 | 4 | Rottinghaus Scott T. — Chief Medical Officer | Grant/award (A): 1,650 @ $0 · Grant/award (A): 5,225 @ $0 · Tax withholding (F): 3,413 @ $14.25 | EDGAR |
| 2026-02-13 | 4 | Or Yat Sun — Chief Scientific Officer | Grant/award (A): 1,650 @ $0 · Grant/award (A): 5,225 @ $0 · Tax withholding (F): 3,413 @ $14.25 | EDGAR |
| 2026-02-13 | 4 | Luly Jay R. — President and CEO, Director | Grant/award (A): 4,800 @ $0 · Grant/award (A): 15,200 @ $0 · Tax withholding (F): 6,155 @ $14.25 | EDGAR |
| 2025-12-05 | 4 | Capps Kathleen S. — See Remarks | Sale (S): 323 @ $14.23 | EDGAR |
| 2025-12-05 | 4 | Trout Harry R. III — See Remarks | Sale (S): 542 @ $14.23 | EDGAR |
| 2025-12-05 | 4 | Rottinghaus Scott T. — Chief Medical Officer | Sale (S): 798 @ $14.23 | EDGAR |
| 2025-12-05 | 4 | Luu Brendan — Chief Business Officer | Sale (S): 1,394 @ $14.23 | EDGAR |
| 2025-12-05 | 4 | Kieffer Tara Lynn — Chief Product Strategy Officer | Sale (S): 2,106 @ $14.23 | EDGAR |
| 2025-12-05 | 4 | Or Yat Sun — Chief Scientific Officer | Sale (S): 2,390 @ $14.23 | EDGAR |
| 2025-12-05 | 4 | Luly Jay R. — President and CEO, Director | Sale (S): 4,743 @ $14.23 | EDGAR |
| 2025-12-03 | 4 | Capps Kathleen S. — See Remarks | Tax withholding (F): 85 @ $14.12 · Sale (S): 207 @ $13.96 | EDGAR |
| 2025-12-03 | 4 | Trout Harry R. III — See Remarks | Tax withholding (F): 105 @ $14.12 · Sale (S): 380 @ $13.96 | EDGAR |
| 2025-12-03 | 4 | Luu Brendan — Chief Business Officer | Tax withholding (F): 498 @ $14.12 | EDGAR |
| 2025-12-03 | 4 | Kieffer Tara Lynn — Chief Product Strategy Officer | Tax withholding (F): 753 @ $14.12 | EDGAR |
| 2025-12-03 | 4 | Or Yat Sun — Chief Scientific Officer | Tax withholding (F): 753 @ $14.12 | EDGAR |
| 2025-12-03 | 4 | Luly Jay R. — President and CEO, Director | Tax withholding (F): 1,885 @ $14.12 | EDGAR |
| 2025-11-26 | 4 | Capps Kathleen S. — See Remarks | Grant/award (A): 3,163 @ $0 · Grant/award (A): 6,325 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Trout Harry R. III — See Remarks | Grant/award (A): 6,463 @ $0 · Grant/award (A): 12,925 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Luu Brendan — Chief Business Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Kieffer Tara Lynn — Chief Product Strategy Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Kowalsky Matthew Paul — Chief Legal Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Rottinghaus Scott T. — Chief Medical Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Or Yat Sun — Chief Scientific Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Luly Jay R. — President and CEO, Director | Grant/award (A): 310,000 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Rottinghaus Scott T. — Chief Medical Officer | Tax withholding (F): 2,217 @ $6.99 | EDGAR |
| 2025-03-14 | 4 | Peterson Kristine — Director | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Vance Terry — Director | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Russell Lesley — Director | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Hata Yujiro S — Director | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | FOLETTA MARK G — Director | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | CARTER BRUCE L A — Director | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Luu Brendan — Chief Business Officer | Grant/award (A): 7,500 @ $0 · Tax withholding (F): 3,326 @ $5.59 | EDGAR |
| 2025-02-14 | 4 | Kieffer Tara Lynn — Chief Product Strategy Officer | Grant/award (A): 7,500 @ $0 · Tax withholding (F): 3,326 @ $5.59 | EDGAR |
| 2025-02-14 | 4 | Rottinghaus Scott T. — Chief Medical Officer | Grant/award (A): 9,750 @ $0 · Tax withholding (F): 2,861 @ $5.59 | EDGAR |
| 2025-02-14 | 4 | Or Yat Sun — Chief Scientific Officer | Grant/award (A): 9,750 @ $0 · Tax withholding (F): 4,324 @ $5.59 | EDGAR |
| 2025-02-14 | 4 | MELLETT PAUL J — Chief Fin. & Admin Officer | Grant/award (A): 7,500 @ $0 · Tax withholding (F): 3,326 @ $5.59 | EDGAR |
| 2025-02-14 | 4 | Luly Jay R. — President and CEO, Director | Grant/award (A): 25,500 @ $0 · Tax withholding (F): 7,484 @ $5.59 | EDGAR |
| 2025-02-12 | 4 | Luly Jay R. — President and CEO, Director | Purchase (P): 45,000 @ $5.69 | EDGAR |
Recent 8-K events — ENANTA PHARMACEUTICALS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-18 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ENTA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →